HC Andersen Capital Events 28/03: Meet the top management in InDex Pharmaceuticals

HC Andersen Capital is hosting a digital event where you can meet and ask questions directly to the top management. It is free for all to attend.

InDex Pharmaceuticals - Update on recently announced results of PK-study with cobitolimod
Meet and ask questions to CEO Jenny Sundqvist and CDO Eva Arlander from InDex Pharmaceuticals. CEO Jenny Sundqvist will give a recap of the company and its on-going phase III program and CDO Eva Arlander will give an update on the recently announced results of the PK-study with cobitolimod.  

InDex Pharmaceuticals is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options. The company’s lead asset is the drug candidate cobitolimod, which is in late-stage clinical development for the treatment of moderate to severe ulcerative colitis – a debilitating, chronic inflammation of the large intestine. InDex is based in Stockholm, Sweden. The company’s shares (ticker INDEX) are traded on Nasdaq First North Growth Market Stockholm.  

Disclaimer: HC Andersen Capital receives payment from InDex Pharmaceuticals for a DigitalIR/Corporate Visibility agreement./ Claus Thestrup 10.10 AM 22-03-2023.

Tuesday 28th of March, 15:00 - 15:30

Sign up via. link


Disclaimer: HC Andersen Capital receives payment from the companies mentioned for a DigitalIR/Corporate Visibility agreement. The content is not buy or sell recommendations. 

Mie Halse
Head of Digital and Events
mie@hcandersencapital.dk
+45 28746640
 

HC Andersen Capital digitizes the relationship between listed companies and investors. We work long-term for companies that want more visibility in the market. #DemocraticIR - HC Andersen Capital works to democratize access to the financial market.